Literature DB >> 19876719

The expression of HMGB1 protein and its receptor RAGE in human malignant tumors.

Nora Kostova1, Stanislava Zlateva, Iva Ugrinova, Evdokia Pasheva.   

Abstract

High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein discovered to be released in the extracellular medium as a response to various stimuli and implicated in cancerogenesis. High HMGB1 levels are reported in a variety of tumor types, but there are few data relating HMGB1 to the histological grade or to a particular cell type and cellular localization. We studied the expression of HMGB1 protein in malignant human tumors of different differentiation level and in tumor metastasis. In all tumor tissues, the protein level is elevated. In moderately differentiated carcinomas, the localization of the protein is perinuclear, while in the low differentiated; there is a tendency for non-specific nuclear localization. HMGB1 protein and its receptor RAGE are identified as a ligand-receptor pair that plays an important role in regulating the invasiveness of tumor cells. RAGE is not produced in all of the tested tumor specimens. We found high level of expression in hepatocellular, colorectal, and breast cribriform carcinomas, but not in malignant testicular specimens. Probably, the RAGE synthesis is related to distinctive tumor types. In metastatic cells, RAGE exhibits higher level of expression losing its specific granular cytosolic pattern characteristic for the primary tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19876719     DOI: 10.1007/s11010-009-0305-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  39 in total

Review 1.  HMG1 and 2: architectural DNA-binding proteins.

Authors:  J O Thomas
Journal:  Biochem Soc Trans       Date:  2001-08       Impact factor: 5.407

Review 2.  HMGB proteins and gene expression.

Authors:  Alessandra Agresti; Marco E Bianchi
Journal:  Curr Opin Genet Dev       Date:  2003-04       Impact factor: 5.578

3.  Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.

Authors:  A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

4.  Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa.

Authors:  Y Y Xiang; D Y Wang; M Tanaka; M Suzuki; E Kiyokawa; H Igarashi; Y Naito; Q Shen; H Sugimura
Journal:  Int J Cancer       Date:  1997-02-20       Impact factor: 7.396

5.  Specific recognition of cruciform DNA by nuclear protein HMG1.

Authors:  M E Bianchi; M Beltrame; G Paonessa
Journal:  Science       Date:  1989-02-24       Impact factor: 47.728

6.  Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.

Authors:  Hiroki Kuniyasu; Naohide Oue; Atsuko Wakikawa; Hideo Shigeishi; Norimasa Matsutani; Kazuya Kuraoka; Reiko Ito; Hiroshi Yokozaki; Wataru Yasui
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

7.  High mobility group protein-1 (HMG-1) is a unique activator of p53.

Authors:  L Jayaraman; N C Moorthy; K G Murthy; J L Manley; M Bustin; C Prives
Journal:  Genes Dev       Date:  1998-02-15       Impact factor: 11.361

8.  Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation.

Authors:  M Passalacqua; A Zicca; B Sparatore; M Patrone; E Melloni; S Pontremoli
Journal:  FEBS Lett       Date:  1997-01-06       Impact factor: 4.124

9.  Differential expression of nuclear HMG1, HMG2 proteins and H1(zero) histone in various blood cells.

Authors:  P Cabart; I Kalousek; D Jandová; Z Hrkal
Journal:  Cell Biochem Funct       Date:  1995-06       Impact factor: 3.685

10.  High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.

Authors:  U Andersson; H Wang; K Palmblad; A C Aveberger; O Bloom; H Erlandsson-Harris; A Janson; R Kokkola; M Zhang; H Yang; K J Tracey
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

View more
  61 in total

1.  High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.

Authors:  Wei Jiang; Zhiming Wang; Xinying Li; Xuegong Fan; Yankun Duan
Journal:  Pathol Oncol Res       Date:  2011-09-07       Impact factor: 3.201

2.  The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma.

Authors:  Toru Takeda; Hiroto Izumi; Shohei Kitada; Hidetaka Uramoto; Takashi Tasaki; Li Zhi; Xin Guo; Yuichiro Kawatsu; Tomoko Kimura; Seichi Horie; Atsunori Nabeshima; Hirotsugu Noguchi; Ke-Yong Wang; Yasuyuki Sasaguri; Kimitoshi Kohno; Sohsuke Yamada
Journal:  Tumour Biol       Date:  2014-07-26

3.  Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.

Authors:  Liguo Lin; Kaihua Zhong; Zhongkai Sun; Guozhong Wu; Guodong Ding
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

4.  Constitutive release of CPS1 in bile and its role as a protective cytokine during acute liver injury.

Authors:  Min-Jung Park; Louis G D'Alecy; Michelle A Anderson; Venkatesha Basrur; Yongjia Feng; Graham F Brady; Dong-Il Kim; Jun Wu; Alexey I Nesvizhskii; Joerg Lahann; Nicholas W Lukacs; Robert J Fontana; M Bishr Omary
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-12       Impact factor: 11.205

5.  Increased expression of HMGB3: a novel independent prognostic marker of worse outcome in patients with esophageal squamous cell carcinoma.

Authors:  Jing Gao; Zhengzhi Zou; Jing Gao; Haifang Zhang; Zhicai Lin; Yaya Zhang; Xianyang Luo; Changhua Liu; Jingdun Xie; Chengfu Cai
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

6.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

Review 7.  Potential role of High mobility group box 1 in hepatocellular carcinoma.

Authors:  Rong-Rong Zhou; Xu-Yuan Kuang; Yan Huang; Ning Li; Ming-Xiang Zou; Dao-Lin Tang; Xue-Gong Fan
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

8.  Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma.

Authors:  Wenna Shi; Lihui Su; Qianqian Li; Lidan Sun; Jing Lv; Jun Li; Baoquan Cheng
Journal:  Tumour Biol       Date:  2014-06-27

9.  High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues.

Authors:  Jordana Todorova; Evdokia Pasheva
Journal:  Oncol Lett       Date:  2011-10-24       Impact factor: 2.967

10.  Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2012-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.